Dapagliflozin - AstraZeneca

Drug Profile

Dapagliflozin - AstraZeneca

Alternative Names: Andatang; BMS-512148; DAPA; Dapagliflozin propanediol; Farxiga; Forxiga; Oxra

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bristol-Myers Squibb; Ono Pharmaceutical; University Medical Center Groningen; Uppsala University
  • Class Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Preregistration Type 1 diabetes mellitus
  • Phase III Chronic heart failure; Renal failure
  • Phase II Kidney disorders; Obesity

Most Recent Events

  • 01 Oct 2018 Pooled efficacy data from the phase III DEPICT 1 and 2 trials in Type 1 diabetes mellitus presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
  • 11 Sep 2018 AstraZeneca and Bristol-Myers Squibb completes the phase III DECLARE-TIMI58 trial for Type-2 diabetes mellitus (add-on therapy, patients at high risk of a cardiovascular event) in USA, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, South Korea, Mexico, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom and Vietnam (PO) (NCT01730534)
  • 27 Aug 2018 AstraZeneca initiates the phase III DELIVER trial for Chronic heart failure in USA and Canada (PO) (NCT03619213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top